Semaglutide weight loss brand names: what the UK actually licenses

Why does semaglutide have different brand names for weight loss?

Pharmaceutical companies sometimes bring the same active molecule to market under different brand names when they seek approval for additional clinical indications. Novo Nordisk first licensed semaglutide as Ozempic for type 2 diabetes, then conducted a separate, large clinical programme (the STEP trials) to establish its safety and effectiveness specifically for weight management. That evidence base led to a distinct product: Wegovy, approved at a higher maintenance dose of 2.4 mg weekly, with its own prescribing criteria and patient information leaflet.

The STEP 1 trial, published in the New England Journal of Medicine, found an average body-weight reduction of around 15% over 68 weeks among adults without diabetes — a result that underpinned both the MHRA's approval and NICE's subsequent recommendation. Ozempic was never studied or approved at those doses for weight loss, which is why using it outside its licensed indication for diabetes is not the same as using Wegovy.

The practical upshot: if a prescriber is considering semaglutide for your weight, they are prescribing Wegovy, not Ozempic. If you want to understand exactly which semaglutide brand applies to your situation, conflating the two (as social media frequently does) can lead people toward medicines obtained without a valid assessment, which carries real clinical risk.

What about the newer semaglutide weight loss products, are there more brands now?

Yes, and the picture shifted significantly in the first half of 2026. On 14 April 2026 the MHRA approved a dedicated single-dose 7.2 mg Wegovy pen, offering a higher maintenance dose for adults with a BMI of 30 or above. Trials at this dose reported average weight loss of around 20.7% over 72 weeks, narrowing the gap with tirzepatide results. That pen is still Wegovy, the same brand, a new maximum dose.

Then, on 11 June 2026, the MHRA approved Wegovy tablets as the UK's first oral GLP-1 medicine licensed for weight management. This is a once-daily tablet containing semaglutide formulated with an absorption enhancer called SNAC. The maintenance dose is 25 mg daily. It requires no refrigeration, which makes it genuinely more practical for many people. The OASIS 4 phase 3 trial found an average weight loss of around 13.6% over 64 weeks versus placebo; among participants who stayed fully adherent, that figure rose to around 16.6%.

Rybelsus is also an oral semaglutide tablet, but it is licensed for type 2 diabetes at much lower doses (3 mg, 7 mg, and 14 mg). Its strengths are entirely separate from the Wegovy tablet schedule and it must not be treated as an alternative weight-loss tablet. If you want to understand the full landscape of semaglutide brands in the UK, that page covers each product clearly.

Which semaglutide brand names does the NHS provide for weight loss?

The NHS does not provide every licensed semaglutide product automatically. NICE recommended Wegovy injection under technology appraisal TA875, but only within specialist weight management services, for a maximum of two years, and for adults meeting specific BMI and comorbidity thresholds. Ethnic-background adjustments lower those BMI thresholds by 2.5 kg/m² for several groups. NHS waiting lists for these services are commonly long in most areas of England.

Wegovy tablets have not yet been appraised by NICE, so they are not available on the NHS at this stage. A NICE appraisal would need to take place first. The NICE guidance on semaglutide for weight management (TA875) explains the current NHS eligibility criteria in full, and it is worth reading if you are trying to establish whether you qualify. One practical check you can do in under a minute: visit that NICE page and look at recommendation 1.1, it lists the exact BMI thresholds and comorbidity requirements, so you can see at a glance whether you fall within the current NHS scope before speaking to your GP.

For those who do not meet NHS criteria, or who prefer not to wait, private treatment through a regulated pharmacy is the other route. That means a genuine prescription following a proper clinical assessment, not a workaround. You can read more about the broader context of semaglutide for weight loss to understand how the two routes compare.

What should you know about semaglutide's side effects before starting?

Across all semaglutide brands used for weight management, the side effect profile is broadly similar. Gastrointestinal symptoms (nausea, diarrhoea, constipation, indigestion) are the most common. They tend to be most noticeable after starting treatment or after a dose increase, and they often settle within days to a couple of weeks as the body adjusts. Fatigue and headache are also reported by some people.

More serious but uncommon effects include acute pancreatitis, which the MHRA highlighted in a Drug Safety Update in January 2026. Severe, persistent stomach pain that spreads to the back (with or without vomiting) should be treated as urgent and assessed by a doctor promptly. Gallbladder problems and signs of allergic reaction are also listed in prescribing information and warrant immediate attention.

The NHS patient information on semaglutide covers the full side effect profile clearly, including which symptoms to monitor and when to seek help. Anyone experiencing side effects they are unsure about should contact their prescriber rather than adjusting their dose independently. A prescriber who genuinely cares about clinical outcomes (rather than just dispensing) will want to hear from you.

Semaglutide is not recommended during pregnancy, while breastfeeding, or for those actively trying to conceive. It is not licensed for use in anyone under 18. These are not caveats to weigh up; they are firm prescribing boundaries. Your prescriber will ask about all of this during the consultation. If you have questions about cost or how private treatment is priced, the Wegovy price comparison page sets out what private treatment typically involves.

To explore whether semaglutide-based treatment might be suitable for your circumstances, check your eligibility with our prescribers. There is no fee for the consultation, and it is reviewed the same day by a real clinician registered with the GPhC.